TICKERNERD
Menu
CRVOCRVOHealthcare · Biotechnology

CRVO Stock Forecast: CervoMed, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.57
+3.63% on the day

The 6 Wall Street analysts covering CervoMed, Inc. hold a median 12-month price target of $15 — +483.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$38.9M
Ticker Nerd rank
29 / 100
Median analyst target
$15
Analysts covering
6
Revenue$0.0
Operating income−$6.7M
Net income−$6.6M
Free cash flow−$6.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
−16.8%
YTD
−67.5%
1Y
−72.1%
From 52W high
−74.1%
From 52W low
+14.2%
$2.25
$9.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CervoMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Revisions
69
Accruals
62
Growth
36
Volatility
35
Momentum
28
Issuance
28
Value
18
Quality
9

Size (84): Smaller than most of the companies we track.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26CRVOHigh $25Median $15Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $7Median $15High $25

The green dot is the last close — the median target sits +483.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
10 Aug 2026Canaccord GenuityMaintainsBuy$27 → $18
15 July 2026HC Wainwright & Co.ReiteratesBuy$25
15 July 2026HC Wainwright & Co.ReiteratesBuy—
13 July 2026HC Wainwright & Co.ReiteratesBuy$25
13 July 2026HC Wainwright & Co.ReiteratesBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy$25
9 July 2026HC Wainwright & Co.ReiteratesBuy—
23 Apr 2026HC Wainwright & Co.ReiteratesBuy—
22 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
19 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
18 Mar 2026Roth CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
5 Mar 2026Chardan CapitalMaintainsBuy—
4 Mar 2026D. Boral CapitalMaintainsBuy—
18 Feb 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025Cantor FitzgeraldInitiatesOverweight—
18 Dec 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRVO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRVO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, CervoMed, Inc. returned −72.1% against +17.5% for the S&P 500, dividends included.

CRVO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26CRVOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

CervoMed, Inc. (CRVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.9×

Cheaper than 66% of US stocks

Price / sales
117.3×

Cheaper than 4% of US stocks

Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
−0.5×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−9407.0%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−107.6%

Higher than 13% of US stocks

Return on assets
−60.8%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CervoMed, Inc. (CRVO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CervoMed, Inc. has a market value of $38.9M and an enterprise value of $13.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$30.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$28.0M.

  • Shares outstanding: 13.5M.

  • Trailing P/E: 4.9×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CervoMed, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CRVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRVOCervoMed, Inc.$38.9M
29
LITSLite Strategy, Inc.$39.6M
31
CELUCelularity, Inc.$39.9M
19
FLNAFilana Therapeutics, Inc.$37.3M
59
KPTIKaryopharm Therapeutics, Inc.$36.3M
55
VERUVeru, Inc.$41.6M
42
ATYRaTyr Pharma, Inc.$42.2M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CervoMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRVO news & analysis

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

GlobeNewsWire · 10 Sept 2026positive

CervoMed announced that initial results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted as a late-breaking oral session at the ISFTD 2026 Annual Meeting. The presentation will highlight 12-week biomarker data from the trial.

Why it matters — A late-breaking oral presentation at a major international conference signals notable scientific recognition for CervoMed's neflamapimod program in nfvPPA and offers CRVO watchers an early glimpse at the trial's 12-week biomarker data.

CervoMed to Participate in September Investor Conferences

GlobeNewsWire · 8 Sept 2026neutral

CervoMed Inc. announced that its management will participate in investor conferences during September. The clinical-stage biotechnology company, which develops treatments for age-related brain disorders, released this notice on September 8, 2026.

Why it matters — CRVO watchers would care because the company's management will be presenting to the investor community, offering potential visibility into the company's progress.

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 10 Aug 2026positive

CervoMed reported its Q2 2026 financial results and corporate updates, highlighting progress toward a strategic partnership for a Phase 3 trial of neflamapimod in DLB, new supportive clinical data, and two equity financings raising approximately $20.5 million to extend its cash runway through Q3 2027.

Why it matters — A CRVO watcher would care because the company is advancing its lead asset neflamapimod toward a pivotal Phase 3 trial for DLB, has secured regulatory designation in the UK, and raised funds to support operations through late 2027.

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 5 Aug 2026neutral

CervoMed announced that its management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, held in Boston on August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

Why it matters — A CervoMed watcher would care because the conference gives management a venue to publicly discuss recent developments in the company's lead clinical program, neflamapimod.

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

GlobeNewsWire · 4 Aug 2026positive

CervoMed announced that neflamapimod has been awarded an Innovation Passport designation under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). The designation is designed to support accelerated time to market and help expedite patient access to potentially transformative investigational medicines.

Why it matters — A CRVO watcher would care because the ILAP Innovation Passport could help accelerate regulatory review and market access for neflamapimod in the UK, a potential milestone for the company's lead dementia candidate.

FAQ

Frequently asked questions about CRVO stock

What is the CRVO stock price forecast for 2026-2027?

The 6 Wall Street analysts covering CervoMed, Inc. have a median 12-month price target of $15, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRVO stock a buy right now?

Of the 6 analysts covering CervoMed, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CervoMed, Inc. 29 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRVO?

As at 11 Sept 2026, CervoMed, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will CRVO stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +483.7% from the last close, and Ticker Nerd's factor model ranks CervoMed, Inc. 29 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRVO stock forecast for 2030?

No analyst covering CervoMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.

How has CRVO stock performed over the past year?

CervoMed, Inc. returned -72.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CervoMed, Inc. do?

CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders.

What is the latest news on CRVO?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026". CervoMed announced that initial results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted as a late-breaking oral session at the ISFTD 2026 Annual Meeting. The presentation will highlight 12-week biomarker data from the trial.

Company

About CervoMed, Inc.

CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The company’s current work centers on advancing CNS-focused therapeutics designed to address degenerative diseases of the brain, with a lead program built around neflamapimod, an investigational orally administered small molecule intended to act on synaptic dysfunction and related neurodegenerative processes. CervoMed’s pipeline targets conditions such as dementia with Lewy bodies and other disorders affecting cognition and neurological function, reflecting its role in the specialized biopharmaceutical sector. As a public company, CervoMed operates within the broader healthcare innovation market, where clinical development, regulatory progress, and therapeutic differentiation are central to its business model. Headquartered in Boston, Massachusetts, CervoMed Inc. serves as a focused small-cap biotechnology participant developing novel approaches for unmet neurological needs.

CEO Dr. John J. Alam M.D. · 15 employees · United States · https://www.cervomed.com